Clarus Therapeutics to Report Third Quarter 2021 Financial and Operating Results
Clarus Therapeutics to Report Third Quarter 2021 Financial and Operating Results
NORTHBROOK, Ill., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. ("Clarus") (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced it will release its third quarter 2021 financial and operating results on Thursday, November 18, 2021, after the market closes.
亚洲网伊利诺伊州诺斯布鲁克11月17日电克拉鲁斯治疗控股公司(“克拉鲁斯”)(纳斯达克代码：CRXT)今天宣布，它将在2021年11月18日(星期四)市场收盘后公布2021年第三季度的财务和经营业绩。该公司致力于通过推进男性和女性的雄激素和代谢疗法来为未得到满足的医疗需求提供解决方案。
Clarus will host a conference call on Thursday, November 18, 2021, at 5:15 p.m. ET to discuss the results. The dial-in numbers are (844) 249-2007 for domestic callers and (224) 619-3902 for international callers. The conference ID number is 1354439. A live webcast and replay of the conference call will be accessible through the Investors section of Clarus Therapeutics' website at Investors.ClarusTherapeutics.com.
Clarus将于2021年11月18日(星期四)下午5点15分主持电话会议。ET讨论结果。国内来电的拨入号码是(844)249-2007，国际来电的拨入号码是(224)619-3902。会议ID号码是1354439。电话会议的现场网络直播和重播可通过Clarus治疗公司网站的投资者部分收看，网址为Investors.ClarusTreeutics.com。
About Clarus Therapeutics Holdings, Inc.
Clarus Therapeutics Holdings, Inc. is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women – including potential therapies for orphan indications. Clarus Therapeutics' first commercial product is JATENZO® (testosterone undecanoate). For more information, visit www.clarustherapeutics.com and www.jatenzo.com. Follow us on Twitter (@Clarus_Thera) and LinkedIn (Clarus Therapeutics).
克拉鲁斯治疗控股公司简介克拉鲁斯治疗控股公司是一家制药公司，在为男性和女性开发雄激素和代谢疗法方面拥有专业知识，包括针对孤儿适应症的潜在疗法。Clarus Treeutics的第一个商业化产品是JATENZO®(十一酸睾酮)。欲了解更多信息，请访问www.clarusTreateutics.com和www.jatenzo.com。在Twitter(@Clarus_Thera)和LinkedIn(Clarus Treeutics)上关注我们。
Clarus Investor Relations Contact:
Kara Stancell
kstancell@clarustherapeutics.com
(847) 562-4300 x 206
克拉鲁斯投资者关系部联系人：卡拉·斯坦塞尔邮箱：kstancell@clarusTreateutics.com(847) 562-4300 x 206